← Open Payments lookup

NPI 1801561220: Open Payments

NPI 1801561220. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$227 in 12 payments from 8 companies in 2025. Trend: 2023 $311 · 2024 $16 · 2025 $227

Food & beverage: $227
CompanyPaymentsAmount
Bayer Healthcare Pharmaceuticals Inc.2$53
ABBVIE INC.3$52
Amgen Inc.2$31
Ardelyx, Inc.1$27
Novo Nordisk Inc1$17
Astellas Pharma US Inc1$16
Esperion Therapeutics, Inc.1$16
Dexcom, Inc.1$14

Products named: Kerendia, VRAYLAR, OTEZLA, IBSRELA, LINZESS, Ozempic, Veozah, NEXLETOL.